What are the patterns in the incidence of early-onset cancers?

The glob­al health part­ner­ship Gavi is look­ing to ramp up vac­cine ac­cess in Africa through a slate of pro­grams that puts up $1.8 bil­lion to

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

These deals come amid a surge in ADC dealmaking across the pharmaceutical sector. Credit: izusek via Getty Images. Lonza’s subsidiary Synaffix has secured licensing agreements